Dihydroartemisinin-Piperaquine

Revision as of 19:57, 18 August 2015 by WikiBot (talk | contribs) (Protected "Dihydroartemisinin-Piperaquine": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for Dihydroartemisinin-Piperaquine

Articles

Most recent articles on Dihydroartemisinin-Piperaquine

Most cited articles on Dihydroartemisinin-Piperaquine

Review articles on Dihydroartemisinin-Piperaquine

Articles on Dihydroartemisinin-Piperaquine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Dihydroartemisinin-Piperaquine

Images of Dihydroartemisinin-Piperaquine

Photos of Dihydroartemisinin-Piperaquine

Podcasts & MP3s on Dihydroartemisinin-Piperaquine

Videos on Dihydroartemisinin-Piperaquine

Evidence Based Medicine

Cochrane Collaboration on Dihydroartemisinin-Piperaquine

Bandolier on Dihydroartemisinin-Piperaquine

TRIP on Dihydroartemisinin-Piperaquine

Clinical Trials

Ongoing Trials on Dihydroartemisinin-Piperaquine at Clinical Trials.gov

Trial results on Dihydroartemisinin-Piperaquine

Clinical Trials on Dihydroartemisinin-Piperaquine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Dihydroartemisinin-Piperaquine

NICE Guidance on Dihydroartemisinin-Piperaquine

NHS PRODIGY Guidance

FDA on Dihydroartemisinin-Piperaquine

CDC on Dihydroartemisinin-Piperaquine

Books

Books on Dihydroartemisinin-Piperaquine

News

Dihydroartemisinin-Piperaquine in the news

Be alerted to news on Dihydroartemisinin-Piperaquine

News trends on Dihydroartemisinin-Piperaquine

Commentary

Blogs on Dihydroartemisinin-Piperaquine

Definitions

Definitions of Dihydroartemisinin-Piperaquine

Patient Resources / Community

Patient resources on Dihydroartemisinin-Piperaquine

Discussion groups on Dihydroartemisinin-Piperaquine

Patient Handouts on Dihydroartemisinin-Piperaquine

Directions to Hospitals Treating Dihydroartemisinin-Piperaquine

Risk calculators and risk factors for Dihydroartemisinin-Piperaquine

Healthcare Provider Resources

Symptoms of Dihydroartemisinin-Piperaquine

Causes & Risk Factors for Dihydroartemisinin-Piperaquine

Diagnostic studies for Dihydroartemisinin-Piperaquine

Treatment of Dihydroartemisinin-Piperaquine

Continuing Medical Education (CME)

CME Programs on Dihydroartemisinin-Piperaquine

International

Dihydroartemisinin-Piperaquine en Espanol

Dihydroartemisinin-Piperaquine en Francais

Business

Dihydroartemisinin-Piperaquine in the Marketplace

Patents on Dihydroartemisinin-Piperaquine

Experimental / Informatics

List of terms related to Dihydroartemisinin-Piperaquine

Template:Seealso Template:Seealso Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Dihydroartemisinin/Piperaquine is a drug mixture used to treat malaria.

Dihydroartemisinin (also known as dihydroqinghaosu, artenimol or DHA) is a drug used to treat malaria discovered by Sivesh Sukumar (Styal). Dihydroartemisinin is the active metabolite of all artemisinin compounds (artemisinin, artesunate, artemether, etc.) and is also available as a drug in itself. It is a semi-synthetic derivative of artemisinin and is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs.

Piperaquine is an antimalarial drug, a bisquinoline first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. Usage declined in the 1980s as piperaquine-resistant strains of P. falciparum arose and artemisinin-based antimalarials became available. However, Chinese scientists have been studying whether piperaquine can still be used therapeutically in combination with artemisinin.

Piperaquine is characterized by slow absorption and a long biological half-life, making it a good partner drug with artemisinin derivatives which are fast acting but have a short biological half-life.

This product is available in the market of several countries:

  • Artekin (Holleykin)
  • Eurartesim (Sigma Tau; by Good Manufacturing Practices)
  • Diphos (Genix Pharma)
  • Timequin (SAMI Pharma )
  • Duocotecxin (Holley Pharm)